Appendix 4C Quarterly Activity Report streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting .
Mesoblast LimitedJuly 19, 2021 GMT
NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. The results showed that two doses of remestemcel-L at days 3-5 conferred durable survival benefit through at least 90 days in the pre-specified subgroup of patients under age 65.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Appendix 4C Quarterly Activity Report
Mesoblast LimitedApril 30, 2021 GMT
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021.
“We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ventilation due to COVID-19. These showed that remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old, particularly when used with dexamethasone as part of standard of care. This has the potential to make a substantial impact in outcomes for this critical patient population,” said Silviu Itescu, Chief Executive of Mesoblast.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe .
Mesoblast LimitedApril 29, 2021 GMT
Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old
In these patients the benefit was further increased when remestemcel-L was used with dexamethasone as part of standard of care
Mortality reduction by remestemcel-L was accompanied by increased days alive off mechanical ventilation and reduced days in hospital
Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute